Ranbaxy's indinavir capsules prequalified by WHO
This article was originally published in Scrip
Ranbaxy Laboratories' antiretroviral, indinavir sulfate 400mg capsules, has been prequalified by the World Health Organization (WHO). Ranbaxy now has 19 ARVs on the WHO pre-qualification list. The company has been providing ARV medicines at affordable prices in more than 70 markets worldwide since 2001 and its products are now used by more than 400,000 patients in various developing and underdeveloped countries.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.